Fig. 1: ARF6 promotes primary melanoma formation and progression.

a Schematic diagram showing ARF6 cycles between the GDP-bound inactive form (red) and the GTP-bound active form (blue). b Correlations between the top and the bottom quartile of mRNA expression levels of indicated ARF6 GAPs in primary cutaneous melanoma (the Leeds cohort) with survival of patients, stage I n = 58, stage II n = 88, and stage III n = 26 in each high and low cohort, p values from Cox proportional hazards regression model. c Total ARF6 and ARF6-GTP pulldown in A375 human melanoma cells with or without ectopic ACAP1 expression, n = 1 experiment. d–g Melanocyte-specific deletion of Arf6 restricts tumourigenesis. d Percent of Dct::TVA; Braf^V600E; Cdkn2a^f/f mice that developed tumours within 100 days after Cre injection (tumour induction). n = 90 Arf6 wild-type (Arf6^WT), n = 119 Arf6 floxed (Arf6^f/f), two-sided Fisher’s exact test. e Days to initial tumour detection after Cre injection, two-tailed t-test with Welch’s correction. n = 51 Arf6^WT, n = 58 Arf6^f/f mice. f Rate of tumour growth measured from time of initial detection, n = 52 Arf6^WT, n = 68 Arf6^f/f mice. g Survival of mice (before primary tumour reached 2 cm) after Cre injection (day 0) within 130 days, n = 45 Arf6^WT, n = 54 Arf6^f/f mice, Log-rank (Mantle-Cox) test. See also Supplementary Fig. 1. e–f Solid line within data points = mean. Source data are provided as a Source Data file.